Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma - ScienceDirect (opens in a new tab)

sciencedirect.com · 2009-09-01

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 5 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma - ScienceDirect

sciencedirect.com · 2009-09-01

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Supported

Every claim holds up. All five claims match what the study reports.

  • 5 supported
Open claim evidence
3
Source paper

Source layer

The 22 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5SupportedA randomized trial compared 30% topical ascorbic acid solution in DMSO with 5% imiquimod for basal cell carcinoma.View evidenceHide evidence

Why this verdict

The abstract-level profile describes a randomized trial in 25 patients with 29 biopsy-confirmed basal cell carcinomas comparing topical 30% ascorbic acid in 95% DMSO with topical 5% imiquimod. This matches the story’s design and intervention/comparator framing.

1

Study evidence

At ~8 weeks after treatment, post-treatment biopsy-confirmed complete lesion resolution was 13/15 (86.7%) with topical 30% ascorbic acid in DMSO versus 8/14 (57.1%) with topical imiquimod (p < 0.05, Chi-square).86.7% vs 57.1% (lesion-level complete resolution); p < 0.05 (Chi-square)

“Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod”
Claim 2 of 5SupportedAfter 8 weeks, lesion resolution confirmed by punch biopsy was 86.7% with ascorbic acid versus 57.1% with imiquimod.View evidenceHide evidence

As stated86.7% vs 57.1%

Why this verdict

The abstract reports post-treatment biopsy-confirmed complete lesion resolution at about 8 weeks in 13/15 lesions (86.7%) in the ascorbic acid group versus 8/14 lesions (57.1%) in the imiquimod group, with p < 0.05 by Chi-square. The profile supports the rates and biopsy-confirmed outcome; the abstract profile says biopsy but does not add much detail about biopsy technique.

1

Study evidence

At ~8 weeks after treatment, post-treatment biopsy-confirmed complete lesion resolution was 13/15 (86.7%) with topical 30% ascorbic acid in DMSO versus 8/14 (57.1%) with topical imiquimod (p < 0.05, Chi-square).86.7% vs 57.1% (lesion-level complete resolution); p < 0.05 (Chi-square)

“Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod”
Claim 3 of 5SupportedThe article says topical ascorbic acid was superior at 8 weeks and non-inferior at 12 weeks for low-risk nodular and superficial basal cell carcinoma.View evidenceHide evidence

Why this verdict

The paper profile states that the authors reported topical ascorbic acid was superior at 8 weeks and non-inferior at 12 weeks to topical imiquimod, and the discussion summary ties this to low-risk nodular and superficial basal cell carcinoma. However, the abstract profile also notes that the 12-week non-inferiority claim is not accompanied by numerical results or statistical details.

1

Study evidence

At ~8 weeks after treatment, post-treatment biopsy-confirmed complete lesion resolution was 13/15 (86.7%) with topical 30% ascorbic acid in DMSO versus 8/14 (57.1%) with topical imiquimod (p < 0.05, Chi-square).86.7% vs 57.1% (lesion-level complete resolution); p < 0.05 (Chi-square)

“Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod”
Claim 4 of 5SupportedAt 30 months, residual hypopigmentation was reported in 70% of the imiquimod group and 0% of the ascorbic acid group.View evidenceHide evidence

As stated70% vs 0%

Why this verdict

The abstract-level profile reports that at approximately 30 months, residual hypopigmentation was observed in 70% of patients in the imiquimod group versus 0% in the ascorbate group. The story’s associational wording matches the available evidence.

1

Study evidence

Topical ascorbic acid was associated with fewer adverse effects than topical imiquimod (abstract statement).

“In addition, ascorbic acid was associated with fewer adverse effects than imiquimod.”
Claim 5 of 5SupportedThe article also states that ascorbic acid was associated with fewer adverse effects than imiquimod.View evidenceHide evidence

Why this verdict

The abstract-level profile states that ascorbic acid was associated with fewer adverse effects than imiquimod. The story reports this as an association, which is consistent with the profile, though the abstract gives no detailed adverse-event rates, definitions, or severity grading.

1

Study evidence

Topical ascorbic acid was associated with fewer adverse effects than topical imiquimod (abstract statement).

“In addition, ascorbic acid was associated with fewer adverse effects than imiquimod.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract reports lesion-level response counts but does not state whether analyses accounted for multiple lesions within the same patient.

    This interpretation-relevant statistical limitation is included in the paper profile but is not among the story’s listed caveats.

    From Randomized controlled trial

  • The abstract does not provide details of randomization procedure, allocation concealment, blinding, or the complete imiquimod dosing regimen.

    The story caveats do not mention these trial-method limitations, which affect confidence in the comparative findings at abstract depth.

    From Randomized controlled trial; Randomized interventional trial (topical treatments)

  • For 30-month hypopigmentation, the abstract does not state denominators, completeness of follow-up, assessment method, blinding, statistical testing, or uncertainty estimates.

    The story reports the 70% versus 0% comparison but does not reflect these material limitations around the long-term cosmetic outcome.

    From Randomized interventional trial (topical treatments)

5 things the story did carry across
  • Randomized human trial comparing topical 30% ascorbic acid in 95% DMSO with topical imiquimod for biopsy-confirmed basal cell carcinoma.
  • Primary short-term efficacy result: at about 8 weeks, post-treatment biopsy showed complete resolution in 13/15 lesions with ascorbic acid versus 8/14 with imiquimod.
  • Authors’ interpretation that ascorbic acid was superior at 8 weeks and non-inferior at 12 weeks for low-risk nodular and superficial basal cell carcinoma.
  • Secondary safety/cosmetic findings: ascorbic acid was associated with fewer adverse effects, and residual hypopigmentation at around 30 months was 70% with imiquimod versus 0% with ascorbate.
  • Small overall sample size: 25 patients and 29 lesions.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoCompare the efficacy of topical 30% ascorbic acid in 95% DMSO versus topical imiquimod for treatment of biopsy-confirmed basal cell carcinoma.Randomized controlled trialExpand

In plain English

Randomized trial (25 patients with 29 biopsy-confirmed basal cell carcinomas) comparing topical 30% ascorbic acid in 95% DMSO (applied twice daily for 8 weeks) versus topical imiquimod. Primary efficacy assessed by post-treatment lesion biopsy at ~8 weeks. At 8 weeks lesion-level complete resolution was 13/15 (86.7%) in the ascorbic acid arm versus 8/14 (57.1%) in the imiquimod arm (p < 0.05, Chi-square). The abstract reports ascorbic acid was superior at 8 weeks and non-inferior at 12 weeks to imiquimod, and that ascorbic acid had fewer adverse effects; residual hypopigmentation at 30-month follow-up was reported as 70% in the imiquimod group versus 0% in the ascorbate group.

Key findings

  • At ~8 weeks after treatment, post-treatment biopsy-confirmed complete lesion resolution was 13/15 (86.7%) with topical 30% ascorbic acid in DMSO versus 8/14 (57.1%) with topical imiquimod (p < 0.05, Chi-square).86.7% vs 57.1% (lesion-level complete resolution); p < 0.05 (Chi-square)
  • Authors report topical ascorbic acid was non-inferior to imiquimod at 12 weeks (no numerical 12-week lesion-level data provided in the abstract).
“Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod”
What this piece can’t prove
  • Abstract reports lesion-level outcomes but does not state whether statistical analyses accounted for multiple lesions within the same patient.

4 further details could not be confirmed from the summary.

2human in vivoCompare safety/tolerability and longer-term cosmetic outcomes (e.g., hypopigmentation) between topical ascorbic acid and imiquimod.Randomized interventional trial (topical treatments)Expand

In plain English

In this randomized trial (25 patients with 29 biopsy-confirmed basal cell carcinomas), the abstract reports that topical 30% ascorbic acid in DMSO was associated with fewer adverse effects than topical imiquimod during/after the treatment period, and that at ~30 months follow-up residual hypopigmentation was observed in 70% of patients in the imiquimod group versus 0% in the ascorbate group. The abstract provides no numeric rates or severity grading for adverse events and does not report statistical testing for these safety/cosmetic outcomes in the text presented.

Key findings

  • Topical ascorbic acid was associated with fewer adverse effects than topical imiquimod (abstract statement).
  • At ~30 months follow-up, 70% of patients in the imiquimod group showed residual hypopigmentation versus 0% in the ascorbate group (abstract statement).70% vs 0% (IMQ vs ascorbate)
“In addition, ascorbic acid was associated with fewer adverse effects than imiquimod.”
What this piece can’t prove
  • Small overall sample size (25 patients, 29 lesions) producing limited precision for safety and long-term cosmetic outcomes.
  • Abstract lacks details on adverse event ascertainment methods, definitions, severity grading, and denominators for reported safety outcomes.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 58 candidate papers

And 52 more candidates considered.